Radiochemotherapy with amifostine cytoprotection for head and neck cancer

Abstract

 A randomized study was conducted to evaluate the protective activity of amifostine (A) against the dose-limiting toxicities of radiochemotherapy (RCT). Patients with head and neck cancer received radiotherapy (2 Gy/day 5 days a week up to 60 Gy) with carboplatin 70 mg/m² on days 1–5 and 21–25 inclusive. Patients either received RCT alone (n=14) or RCT+A at a dose of 500 mg prior to treatment with carboplatin (n=25). There was a significant reduction in the incidence of grade 3/4 mucositis (P<0.0001), acute grade 2 xerostomia (P<0.0001) and grade 3/4 thrombocytopenia (P=0.012) in these patients who received A. The incidence of grade 2 late xerostomia at 12 months is 16.7% and the incidence of loss of taste is 0% in patients treated with A, as opposed to 54.5% and 63.6% in patients who received RCT alone. There were 18 (72%) complete responses (CR) and 6 (24%) partial responses (PR) in patients who received A, compared with 6 (43%) CR and 6 PR (43%) in patients treated with RCT alone. The disease-free survival at 12 months is 85.7% in the RCT+A arm and 78.6% in the RCT alone arm. The use of amifostine reduces the incidence and severity of acute and late toxicities associated with RCT whilst preserving antitumour activity.